We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals
OLMA

97 hedge funds and large institutions have $584M invested in Olema Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

445% more call options, than puts

Call options by funds: $2.91M | Put options by funds: $534K

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

78% more capital invested

Capital invested by funds: $329M → $584M (+$255M)

25.11% more ownership

Funds ownership: 89.34% → 114.44% (+25%)

13% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 31

11% more funds holding

Funds holding: 87 → 97 (+10)

Holders
97
Holders Change
+10
Holders Change %
+11.49%
% of All Funds
1.54%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
18
Increased
35
Reduced
31
Closed
8
Calls
$2.91M
Puts
$534K
Net Calls
+$2.38M
Net Calls Change
+$2.29M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$41.5M
2
DTC
Deep Track Capital
Connecticut
+$19.7M
3
BI
BVF Inc
California
+$15.5M
4
CAM
Cormorant Asset Management
Massachusetts
+$14.5M
5
MB
MPM BioImpact
Massachusetts
+$14.2M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
-$10.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$2.39M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$2.15M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.01M
5
ACM
Aquilo Capital Management
California
-$1.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$3.02M +$1.73M +169,553 +226%
EI
27
EAM Investors
California
$3M +$750K +73,560 +43%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$2.96M -$11.2K -1,100 -0.5%
KCM
29
Kynam Capital Management
New Jersey
$2.9M -$10.9M -1,069,156 -82%
Millennium Management
30
Millennium Management
New York
$2.64M -$545K -53,463 -20%
KCM
31
Kingdon Capital Management
New York
$2.59M +$2.14M +210,000 New
Vontobel Holding
32
Vontobel Holding
Switzerland
$2.03M -$662K -64,945 -28%
Walleye Capital
33
Walleye Capital
New York
$1.94M +$1.6M +157,029 New
ACP
34
Acuta Capital Partners
California
$1.89M +$481K +47,193 +45%
NM
35
Newtyn Management
New York
$1.85M -$255K -25,000 -14%
Two Sigma Investments
36
Two Sigma Investments
New York
$1.63M -$59.8K -5,862 -4%
N
37
Nuveen
North Carolina
$1.24M +$459 +45 +0%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.22M +$387K +38,011 +62%
Goldman Sachs
39
Goldman Sachs
New York
$1.16M +$580K +56,950 +154%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$1.13M +$4.67K +458 +0.5%
ACM
41
Aquilo Capital Management
California
$1.1M -$1.64M -161,125 -64%
Marshall Wace
42
Marshall Wace
United Kingdom
$1.07M +$884K +86,734 New
DCM
43
Driehaus Capital Management
Illinois
$1.07M – – –
BCM
44
Bridgeway Capital Management
Texas
$1.07M -$298K -29,200 -25%
Charles Schwab
45
Charles Schwab
California
$987K – – –
VA
46
VR Adviser
New York
$951K +$785K +77,042 New
SSA
47
Schonfeld Strategic Advisors
New York
$894K -$543K -53,243 -42%
CAM
48
ClariVest Asset Management
California
$813K +$129K +12,700 +24%
Victory Capital Management
49
Victory Capital Management
Texas
$784K +$647K +63,450 New
GCP
50
GSA Capital Partners
United Kingdom
$738K -$429K -42,067 -41%
1
2
3 4 5

OLMA Hedge Fund Activity: Q3 2023 in Review

97 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2023, worth a combined $584M — up 78% from $329M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OLMA positions and 8 closed out — a net gain of 10 holders — while 35 added to existing stakes and 31 trimmed.

The largest buyer was Paradigm Biocapital Advisors, adding an estimated $41.5M. The largest seller was Kynam Capital Management, cutting an estimated $10.9M.

  • 97 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2023, up from 87 in Q2 2023.
  • Funds reported $584M of Olema Pharmaceuticals stock for Q3 2023, up 78% quarter-over-quarter.
  • 18 funds opened new Olema Pharmaceuticals positions in Q3 2023 and 8 closed out, a net change of +10 holders.
  • The largest Olema Pharmaceuticals buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $41.5M added.
  • The largest Olema Pharmaceuticals seller in Q3 2023 was Kynam Capital Management, an estimated $10.9M sold.

Based on aggregated 13F filings for Q3 2023.